Резкое увеличение числа пациентов с хронической обструктивной болезнью легких
(ХОБЛ), наметившееся в конце XX в., грозит стать серьезным вызовом человечеству и …

Purpose Previous studies demonstrating efficacy and safety of once-daily umeclidinium
(UMEC) in patients with chronic obstructive pulmonary disease (COPD) have included few …

The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with
long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the …

We humans tend to believe that the world has always existed in the form in which we know
it. History is fine as an object of study, but we rarely make the effort to really situate ourselves …

Drugs from the two major classes of bronchodilator; umeclidinium, a long-acting muscarinic
antagonist (LAMA), and vilanterol, a long-acting β2 agonist (LABA), have been combined in …

Background: The impact of hospital emergency care and inward admission for acute
exacerbations of COPD on inhaled maintenance treatment is not well known. Objective …

Abstract Objective Umeclidinium bromide (UMEC) 62.5 μg is a long-acting muscarinic
antagonist (LAMA) that is administered once daily via inhalation for chronic obstructive …

Introduction A combination of fluticasone furoate (FF) and umeclidinium (UMEC) has been
considered for development for the treatment of asthma. The primary objectives were to …

近年来, 慢性阻塞性肺疾病(COPD) 发病率不断上升, 病死率逐渐增加, 严重威胁着全世界患者的
生命健康. 由于胆碱能神经及其受体的变化在COPD 的发病过程中起重要的作用 …

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-
documented monographs on drugs that are newly released or are in late phase 3 trials. The …